Market Cap 218.10M
Revenue (ttm) 0.00
Net Income (ttm) -45.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 479,500
Avg Vol 1,254,512
Day's Range N/A - N/A
Shares Out 30.68M
Stochastic %K 16%
Beta 3.37
Analysts Strong Sell
Price Target $23.22

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 561 8600
Address:
155 Bovet Road, Suite 303, San Mateo, United States
valueforme
valueforme Aug. 23 at 3:20 AM
$SGMT Haven't been here for a while, but I still watching pretty closely. f it drops below $6, I might reenter. Those who track SEC filings might have noticed the change of the auditor in the middle of the year without any well explained reasons. @mailman1961 you know this way better than me, why do companies do that in the middle of year? I want to say this is something-something M&A preparation to avoid a conflict of interest when acquirer has the same auditor as the target. But it's too speculative https://www.sec.gov/ix?doc=/Archives/edgar/data/0001400118/000110465925081630/tm2524100d1_8k.htm
3 · Reply
shibadad
shibadad Aug. 22 at 8:02 PM
$SGMT Someone took a flyer and bought 100 Jan 20 calls. Not a large trade but it's an interesting play.
0 · Reply
StockConsultant
StockConsultant Aug. 22 at 1:30 PM
$SGMT Sagimet Biosciences stock watch, pullback to 7.02 double support area at https://stockconsultant.com/?SGMT
0 · Reply
cats44ever
cats44ever Aug. 21 at 9:02 PM
$SGMT Next potential dramatic impetus will be at or around the Weill Prostrate Cancer trial results expected in Q4 2025.
1 · Reply
cats44ever
cats44ever Aug. 21 at 8:52 PM
$SGMT The problem with MASH & hair loss is that the majority of people that suffer this are women (over 60%) & many women would rather die than lose hair for a disease that is not life threatening... and I believe that's why Andrea Tan of Goldman Sachs downgraded them last year on June 28th last year after Ph2 results were better known. In many ways the hidden success of the Ascletis Acne trial is the re-affirmation of the safety of Denifanstat (only hair loss in the Placebo group)
1 · Reply
cats44ever
cats44ever Aug. 21 at 8:42 PM
$SGMT Just wanted to add a thought regarding the GBM trial & the way Ascletis abandoned it & how lucky we are that the Acne trial was such a success. Last year, while we were waiting for Ascletis to announce trial results for GBM &/or Acne, I thought... even if the results didn't satisfy primary/secondary goals, at least we'll establish safety results & disprove the hair loss side effect that seemed to be killing the SGMT MASH potential. I figured that at the very least, even if the Acne trials were a dissapointment, we'd get confirmation (as management claimed during one of the CC's last year), that hair loss was not an issue in the Acne trial. Now I realize that there was the possibility that Ascletis might have just abandoned the Acne trial... without posing any safety data, the way they just did with the GBM trial. We'll never know the safety results on the GBM trial now... and we just have to thank the stars that the Acne trial worked out the way it did!
1 · Reply
Allin33
Allin33 Aug. 21 at 5:28 AM
$SGMT Woodline Partners LP. just purchased 2.5+ mil shares. Zack ranks it a #2 stock (Buy).
0 · Reply
ewewowo
ewewowo Aug. 20 at 10:51 PM
$SGMT never forget that market price does not correlate 1:1 with how the company itself is doing.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 20 at 6:32 PM
$SGMT she's alive...
0 · Reply
JoeBio
JoeBio Aug. 20 at 12:44 PM
0 · Reply
Latest News on SGMT
Sagimet Biosciences' Denifanstat Should Be Worth More Today

Mar 7, 2025, 4:27 PM EST - 6 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today


Sagimet: More Than Just A MASH Drug Development Biotech

Nov 14, 2024, 3:56 PM EST - 10 months ago

Sagimet: More Than Just A MASH Drug Development Biotech


Sagimet Biosciences Announces Leadership Changes

Jul 20, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences Announces Leadership Changes


valueforme
valueforme Aug. 23 at 3:20 AM
$SGMT Haven't been here for a while, but I still watching pretty closely. f it drops below $6, I might reenter. Those who track SEC filings might have noticed the change of the auditor in the middle of the year without any well explained reasons. @mailman1961 you know this way better than me, why do companies do that in the middle of year? I want to say this is something-something M&A preparation to avoid a conflict of interest when acquirer has the same auditor as the target. But it's too speculative https://www.sec.gov/ix?doc=/Archives/edgar/data/0001400118/000110465925081630/tm2524100d1_8k.htm
3 · Reply
shibadad
shibadad Aug. 22 at 8:02 PM
$SGMT Someone took a flyer and bought 100 Jan 20 calls. Not a large trade but it's an interesting play.
0 · Reply
StockConsultant
StockConsultant Aug. 22 at 1:30 PM
$SGMT Sagimet Biosciences stock watch, pullback to 7.02 double support area at https://stockconsultant.com/?SGMT
0 · Reply
cats44ever
cats44ever Aug. 21 at 9:02 PM
$SGMT Next potential dramatic impetus will be at or around the Weill Prostrate Cancer trial results expected in Q4 2025.
1 · Reply
cats44ever
cats44ever Aug. 21 at 8:52 PM
$SGMT The problem with MASH & hair loss is that the majority of people that suffer this are women (over 60%) & many women would rather die than lose hair for a disease that is not life threatening... and I believe that's why Andrea Tan of Goldman Sachs downgraded them last year on June 28th last year after Ph2 results were better known. In many ways the hidden success of the Ascletis Acne trial is the re-affirmation of the safety of Denifanstat (only hair loss in the Placebo group)
1 · Reply
cats44ever
cats44ever Aug. 21 at 8:42 PM
$SGMT Just wanted to add a thought regarding the GBM trial & the way Ascletis abandoned it & how lucky we are that the Acne trial was such a success. Last year, while we were waiting for Ascletis to announce trial results for GBM &/or Acne, I thought... even if the results didn't satisfy primary/secondary goals, at least we'll establish safety results & disprove the hair loss side effect that seemed to be killing the SGMT MASH potential. I figured that at the very least, even if the Acne trials were a dissapointment, we'd get confirmation (as management claimed during one of the CC's last year), that hair loss was not an issue in the Acne trial. Now I realize that there was the possibility that Ascletis might have just abandoned the Acne trial... without posing any safety data, the way they just did with the GBM trial. We'll never know the safety results on the GBM trial now... and we just have to thank the stars that the Acne trial worked out the way it did!
1 · Reply
Allin33
Allin33 Aug. 21 at 5:28 AM
$SGMT Woodline Partners LP. just purchased 2.5+ mil shares. Zack ranks it a #2 stock (Buy).
0 · Reply
ewewowo
ewewowo Aug. 20 at 10:51 PM
$SGMT never forget that market price does not correlate 1:1 with how the company itself is doing.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 20 at 6:32 PM
$SGMT she's alive...
0 · Reply
JoeBio
JoeBio Aug. 20 at 12:44 PM
0 · Reply
rational1
rational1 Aug. 20 at 12:40 PM
0 · Reply
gsgofish
gsgofish Aug. 20 at 12:17 PM
$SGMT Is that the Acne program?
5 · Reply
Zip_it_up
Zip_it_up Aug. 20 at 9:28 AM
$SGMT this getting ripe to add?
1 · Reply
JoeBio
JoeBio Aug. 20 at 12:40 AM
$SGMT Does this explain recent price drop - See page 49 - Ascletis announced cessation of China GBM program in August 2025. https://ir.sagimet.com/static-files/df000576-3450-4a62-9b8a-2ce2bea46f94 WTF management!
2 · Reply
JoeBio
JoeBio Aug. 19 at 8:24 PM
$SGMT so wen bleeding stop before complete hemorrhage?
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 19 at 2:53 PM
$SGMT these take downs are all on low volume.
2 · Reply
AnyaGirl
AnyaGirl Aug. 19 at 2:16 PM
$SGMT worthless. we all got bamboozled. shouldve sold at 11 and never looked back.
0 · Reply
Moshego
Moshego Aug. 19 at 10:20 AM
$SGMT Classical head & shoulder breakdown
0 · Reply
John___wick44
John___wick44 Aug. 18 at 12:50 AM
$SGMT with gbm trial being terminated u would think results were not too compelling. no meaningful data for 6-8 months you are at the mercy of the market. interesting to see how low it goes when a correction does occur at some point during this period.
2 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Aug. 15 at 9:06 PM
$SGMT Are we all missing something in FASN that institutional science backers know to avoid over other therapeutic modalities? We are bullish in FASN tech for mash but for some reason neither science institutional investors nor well capitalized biotech/pharma fail to support these trials. What are we missing? Kindly provide some substantive rationale.
2 · Reply
rational1
rational1 Aug. 15 at 2:59 PM
$SGMT There have been ZERO additional shares placed by ATM financing yet. Company simply has switched broker/dealers from Cantor to Leerink. Same exact number of shares, no change. I am buying this pullback.
3 · Reply
AnyaGirl
AnyaGirl Aug. 15 at 1:54 PM
$SGMT can we see 4-5$?
1 · Reply